1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sanbio Co Ltd.

Sanbio Co Ltd.

5.51
USD
-0.56
(-9.23%)
Dec 10Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
5.34
82.39
26.93
21.15
10.81
15.27
8.75
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-15.41
44.3
-22.66
-40.87
-86.82
-60.15
-100.87
-65.36
-90.3
-95.96
-40.47
-40.47
-52.54
- -
Free Cash Flow per Basic Share
-3.18
-5.65
-32.61
-42.17
-42.73
-81.86
-113.91
-103.37
-127.45
-128.45
-73.77
-50.65
-51.87
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-49.53
-2.2
142.63
101.83
18.75
179.08
211
161.19
39.28
69.1
41.09
24.85
174.29
150.16
Tangible Book Value per Share
-49.53
-2.2
142.63
101.66
18.63
179.03
210.74
160.16
38
69.08
40.45
24.23
173.73
149.6
Basic Weighted Avg Shares
38
39
44
45
45
49
51
52
52
58
65
71
73
76
Sales/Revenue/Turnover
204
3,229
1,175
950
491
742
447
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-285.99
69.64
-95.79
-203.49
-892.62
-503.49
-1,226.69
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
4
6
14
27
54
37
40
74
132
25
15
9
8
- -
Net Income, GAAP
-589
1,736
-988
-1,835
-3,940
-2,921
-5,158
-3,386
-4,678
-5,560
-2,644
-2,883
-3,843
- -
Effective Tax Rate (%)
- -
22.08
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-288.54
53.77
-84.14
-193.28
-803.31
-393.81
-1,153.27
- -
- -
- -
- -
- -
- -
- -
Working Capital
-1,984
878
6,772
5,577
2,970
11,992
13,451
10,663
3,888
5,877
4,032
2,604
14,955
13,041
LT Debt
- -
1,100
300
1,150
2,233
4,000
3,500
2,525
2,013
665
397
129
1,110
1,126
Total Equity
-1,963
-87
6,367
4,595
853
8,909
10,930
8,350
2,035
4,429
2,792
1,763
13,605
11,725
Return on Invested Capital (%)
- -
-523.67
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-409.46
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-33.49
-144.65
-59.83
-51.99
-35.12
-90.09
-172.02
-73.24
-126.57
-50.01
- -

Capital Structure

JPY

•

in mil. unless spec.
Jul'25
Apr'27
Jul'27
ST Debt
268
- -
- -
LT Borrowings
263
- -
1,126
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
78
78
Market Capitalization
- -
- -
- -

Working Capital

JPY

•

in mil. unless spec.
Jul'25
Apr'27
Jul'27
Total Current Assets
3,439
- -
13,381
Cash, Cash Equivalents & STI
3,082
- -
12,748
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
143
Total Current Liabilities
649
- -
340
Payables & Accruals
- -
- -
- -
ST Debt
268
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
147.38%
127.98%
671.71%
Free Cash Flow
15.98%
-3.84%
5.15%
Net Income, GAAP
26.36%
9.38%
33.29%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-2.12
-16.96
- -
- -
-40.47
2026
- -
- -
- -
- -
-52.54
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Keita Mori
Full Time Employees
33
Sector
Health technology
Industry
Pharmaceuticals: major
Address
St. Luke Tower Tokyo TY Japan 104-0044
IPO Date
Apr 8, 2015
Website
sanbio.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
SanBio Company Limited (TSE:4592; OTC:SNBIF), a biopharmaceutical company founded in 2001 and headquartered in Tokyo, Japan, with additional facilities in Oakland, California, USA, researches, develops, manufactures, and commercializes regenerative cell therapies using allogeneic mesenchymal stem cells to restore neurological function damaged by disease or injury; its lead product, AKUUGO (vandefitemcel, previously SB623), is a suspension for intracranial implantation targeting chronic traumatic brain injury, ischemic stroke, and Parkinson's disease, while its pipeline also encompasses therapies for eye diseases and other central nervous system disorders through partnerships such as joint development with OcuMension (Hong Kong) Limited and collaboration with D&P Bioinnovations, Inc. for regenerative esophageal implants. The company operates primarily in Japan and the United States, advancing clinical programs with regulatory milestones including conditional approval of AKUUGO by Japan's Ministry of Health, Labour and Welfare in 2024, subsequent partial change applications for manufacturing and marketing in 2025, and an agreement with the U.S. FDA on Phase 3 trial design for traumatic brain injury. Recent developments feature secured commitment lines totaling ¥3 billion from Resona Bank, Mizuho Bank, and Mitsubishi UFJ Financial Group in 2025 for financial stability; a planned international offering to raise up to ¥14.9 billion to fund product launches and clinical trials; revision of expected approval timelines for AKUUGO partial changes; and strategic expansions including interactions for stroke indications in Japan and U.S. market entry, alongside CEO Keita Mori's appointment as Chairman of the Samurai Biotech Association in May 2025.